← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › Other monoclonal antibodies and antibody drug conjugates
bermekimab
L01FX11
Forms & Strengths
- Subcutaneous injection: 200 mg/mL in single-dose pre-filled syringe
Adult Dosing
- Hydradenitis suppurativa: 400 mg subcutaneously once weekly
Pediatric Dosing
- Safety and efficacy in pediatric patients not established
Indications
- Moderate-to-severe hidradenitis suppurativa
Mechanism of Action
- Human monoclonal IgG1 antibody that specifically neutralizes interleukin-1 alpha (IL-1a)
- Reduces inflammatory cascades, neutrophil recruitment, and downstream pro-inflammatory cytokine production
Contraindications
- History of severe hypersensitivity to bermekimab or any of its excipients
- Active severe systemic infections, including active tuberculosis
Adverse Reactions
- Upper respiratory tract infections
- Injection site reactions
- Headache
- Nausea
- Fatigue
- Hypersensitivity reactions
Drug Interactions
- Live vaccines: Avoid concurrent administration with live or live-attenuated vaccines
- Immunosuppressants: Potential for increased immunosuppression and infection risk with concurrent use
- CYP450 substrates: No formal pharmacokinetic drug-interaction studies conducted, but unlikely to be affected
Curated Content: Needs Vetting Before Put to Clinical Use